Overview

Assessing the Effect of Multiple Doses of Zibotentan on the Pharmacokinetics of Single Doses of Combined Oral Contraceptives in Healthy Female Participants of Non-childbearing Potential

Status:
Not yet recruiting

Trial end date:
2022-12-26

Target enrollment:

Participant gender:

Summary

A study to assess the Pharmacokinetics (PK) of combined oral ethinyl estradiol (EE) and levonorgestrel (LNG) in healthy female participants of non-child-bearing potential, when administered alone and in combination with multiple oral doses of zibotentan.

Phase:

Phase 1

Details

Lead Sponsor:

AstraZeneca

Collaborator:

Parexel